Epoprostenol sodium for treatment of pulmonary arterial hypertension

References

• ArcherSRichSPrimary pulmonary hypertension: a vascular biology and translational research “work in progress”Circulation2000102222781279111094047
   PubMed Web of Science ®Google Scholar
• MiuraANakamuraKKusanoKFThree-dimensional structure of pulmonary capillary vessels in patients with pulmonary hypertensionCirculation2010121192151215320479166
   PubMed Web of Science ®Google Scholar
• HumbertMSitbonOSimonneauGTreatment of pulmonary arterial hypertensionN Engl J Med2004351141425143615459304
   PubMed Web of Science ®Google Scholar
• NakamuraKShimizuJKataokaNAltered nano/micro-order elasticity of pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertensionInt J Cardiol2010140110210719073348
   PubMed Web of Science ®Google Scholar
• ChristmanBWMcPhersonCDNewmanJHAn imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertensionN Engl J Med1992327270751603138
   PubMed Web of Science ®Google Scholar
• TuderRMCoolCDGeraciMWProstacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertensionAm J Respir Crit Care Med199915961925193210351941
   PubMed Web of Science ®Google Scholar
• AkagiSNakamuraKMiyajiKMarked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertensionCirc J201074102200220520697180
   PubMed Web of Science ®Google Scholar
• AkagiSMatsubaraHOgawaAPrevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertensionCirc J200771455956417384460
   PubMed Web of Science ®Google Scholar
• AkagiSOgawaAMiyajiKKusanoKItoHMatsubaraHCatecholamine support at the initiation of epoprostenol therapy in pulmonary arterial hypertensionAnn Am Thorac Soc201411571972724716663
   PubMedGoogle Scholar
• RubinLJMendozaJHoodMTreatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trialAnn Intern Med199011274854912107780
   PubMed Web of Science ®Google Scholar
• BarstRJRubinLJLongWAPrimary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study groupN Engl J Med199633452963028532025
   PubMed Web of Science ®Google Scholar
• BadeschDBTapsonVFMcGoonMDContinuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trialAnn Intern Med2000132642543410733441
   PubMed Web of Science ®Google Scholar
• GalièNCorrisPAFrostAUpdated treatment algorithm of pulmonary arterial hypertensionJ Am Coll Cardiol20136225 SupplD60D7224355643
   PubMed Web of Science ®Google Scholar
• McLaughlinVVShillingtonARichSSurvival in primary pulmonary hypertension: the impact of epoprostenol therapyCirculation2002106121477148212234951
   PubMed Web of Science ®Google Scholar
• KempKSavaleLO’CallaghanDSUsefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational studyJ Heart Lung Transplant201231215015822138355
   PubMed Web of Science ®Google Scholar
• BadeschDBMcGoonMDBarstRJLongterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenolJ Rheumatol200936102244224919723905
   PubMed Web of Science ®Google Scholar
• HumbertMSanchezOFartoukhMShort-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot studyEur Respir J19991361351135610445611
   PubMed Web of Science ®Google Scholar
• KuhnKPByrneDWArbogastPGDoyleTPLoydJERobbinsIMOutcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenolAm J Respir Crit Care Med2003167458058612446266
   PubMed Web of Science ®Google Scholar
• ShiraiYYasuokaHTakeuchiTSatohTKuwanaMIntravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single centerMod Rheumatol20132361211122023359006
   PubMed Web of Science ®Google Scholar
• RosenzweigEBKersteinDBarstRJLong-term prostacyclin for pulmonary hypertension with associated congenital heart defectsCirculation199999141858186510199883
   PubMed Web of Science ®Google Scholar
• ThomasICGlassner-KolminCGomberg-MaitlandMLong-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart diseaseInt J Cardiol201316844117412123890862
   PubMed Web of Science ®Google Scholar
• KuoPCJohnsonLBPlotkinJSHowellCDBartlettSTRubinLJContinuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertensionTransplantation19976346046069047158
   PubMed Web of Science ®Google Scholar
• KrowkaMJFrantzRPMcGoonMDSeversonCPlevakDJWiesnerRHImprovement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertensionHepatology199930364164810462369
   PubMed Web of Science ®Google Scholar
• FixOKBassNMDe MarcoTMerrimanRBLong-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenolLiver Transpl200713687588517539008
   PubMed Web of Science ®Google Scholar
• McLaughlinVVGenthnerDEPanellaMMRichSReduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertensionN Engl J Med199833852732779445406
   PubMed Web of Science ®Google Scholar
• SitbonOHumbertMNunesHLong-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survivalJ Am Coll Cardiol200240478078812204511
   PubMed Web of Science ®Google Scholar
• RichSMcLaughlinVVThe effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertensionJ Am Coll Cardiol19993441184118710520810
   PubMed Web of Science ®Google Scholar
• McLaughlinVVMcGoonMDPulmonary arterial hypertensionCirculation2006114131417143117000921
   PubMed Web of Science ®Google Scholar
• TuderRMPathology of pulmonary arterial hypertensionSemin Respir Crit Care Med200930437638519634077
   PubMed Web of Science ®Google Scholar
• StacherEGrahamBBHuntJMModern age pathology of pulmonary arterial hypertensionAm J Respir Crit Care Med2012186326127222679007
   PubMed Web of Science ®Google Scholar
• FujioHNakamuraKMatsubaraHCarvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertensionJ Cardiovasc Pharmacol200647225025516495763
   PubMed Web of Science ®Google Scholar
• OgawaANakamuraKMatsubaraHPrednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertensionCirculation2005112121806181216157769
   PubMed Web of Science ®Google Scholar
• GeraciMWMooreMGesellTGene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysisCirc Res200188655556211282888
   PubMed Web of Science ®Google Scholar
• ZhangSFantozziITignoDDBone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cellsAm J Physiol Lung Cell Mol Physiol20032853L740L75412740218
   PubMed Web of Science ®Google Scholar
• NakamuraKAkagiSOgawaAPro-apoptotic effects of imatinib on pdgf-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertensionInt J Cardiol2012159210010621376411
   PubMed Web of Science ®Google Scholar
• SchermulyRTDonyEGhofraniHAReversal of experimental pulmonary hypertension by pdgf inhibitionJ Clin Invest2005115102811282116200212
   PubMed Web of Science ®Google Scholar
• ClappLHFinneyPTurcatoSTranSRubinLJTinkerADifferential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic amp generation in human pulmonary arteryAm J Respir Cell Mol Biol200226219420111804870
   PubMed Web of Science ®Google Scholar
• AkagiSNakamuraKMatsubaraHProstaglandin i2 induces apoptosis via upregulation of fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertensionInt J Cardiol2013165349950521955608
   PubMed Web of Science ®Google Scholar
• AkagiSNakamuraKMatsubaraHReverse remodeling of pulmonary arteries by high-dose prostaglandini2 therapy. A case reportJ Cardiol Cases201395173176
   Google Scholar
• RichSPogorilerJHusainANTothPTGomberg-MaitlandMArcherSLLong-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertensionChest201013851234123921051399
   PubMed Web of Science ®Google Scholar
• AchcarROYungGLSafferHCoolCDVoelkelNFYiESMorphologic changes in explanted lungs after prostacyclin therapy for pulmonary hypertensionEur J Med Res200611520320716723294
   PubMed Web of Science ®Google Scholar
• GalieNHoeperMMHumbertMESC Committee for Practice Guidelines (CPG)Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (esc) and the european respiratory society (ers), endorsed by the international society of heart and lung transplantation (ishlt)Eur Heart J200930202493253719713419
   PubMed Web of Science ®Google Scholar
• RubinLJGrovesBMReevesJTFrosolonoMHandelFCatoAEProstacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertensionCirculation19826623343387046988
   PubMed Web of Science ®Google Scholar
• SitbonOHumbertMJaïsXLong-term response to calcium channel blockers in idiopathic pulmonary arterial hypertensionCirculation2005111233105311115939821
   PubMed Web of Science ®Google Scholar
• ZuoXRZhangRJiangXUsefulness of intravenous adenosine in idiopathic pulmonary arterial hypertension as a screening agent for identifying long-term responders to calcium channel blockersAm J Cardiol2012109121801180622459309
   PubMed Web of Science ®Google Scholar
• TonelliARAlnuaimatHMubarakKPulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertensionRespir Med2010104448149620004088
   PubMed Web of Science ®Google Scholar
• RaffyOAzarianRBrenotFClinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertensionCirculation19969334844888565165
   PubMed Web of Science ®Google Scholar
• CreveyBJDantzkerDRBowerJSPopatKDWalkerSDHemodynamic and gas exchange effects of intravenous diltiazem in patients with pulmonary hypertensionAm J Cardiol19824935785837058767
   PubMed Web of Science ®Google Scholar
• YoungTELundquistLJCheslerEWeirEKComparative effects of nifedipine, verapamil, and diltiazem on experimental pulmonary hypertensionAm J Cardiol19835111952006571766
   PubMed Web of Science ®Google Scholar
• PackerMMedinaNYushakMAdverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular diseaseJ Am Coll Cardiol1984458909016491082
   PubMed Web of Science ®Google Scholar
• PackerMMedinaNYushakMWienerIDetrimental effects of verapamil in patients with primary pulmonary hypertensionBr Heart J19845211061116743418
   PubMedGoogle Scholar
• SaitoYNakamuraKMiyajiKAcute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertensionJ Pharmacol Sci2012120320621223117888
   PubMed Web of Science ®Google Scholar
• TeraiMTakenakaTMaenoHInhibition of calcium influx in rabbit aorta by nicardipine hydrochloride (yc-93)Biochem Pharmacol19813043753787213424
   PubMed Web of Science ®Google Scholar
• BristowMRGinsburgRLaserJAMcAuleyBJMinobeWTissue response selectivity of calcium antagonists is not due to heterogeneity of [3h]-nitrendipine binding sitesBr J Pharmacol19848223093206329392
   PubMed Web of Science ®Google Scholar
• ChinKMBadeschDBRobbinsIMTwo formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: Epitome-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase iv, open-label, randomized studyAm Heart J20141672218225 e21124439983
   PubMed Web of Science ®Google Scholar
• SitbonODelcroixMBergotEEpitome-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertensionAm Heart J2014167221021724439982
   PubMed Web of Science ®Google Scholar
• RuanCHDixonRAWillersonJTRuanKHProstacyclin therapy for pulmonary arterial hypertensionTex Heart Inst J201037439139920844610
   PubMed Web of Science ®Google Scholar
• OlssonKMDelcroixMGhofraniHAAnticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (compera)Circulation20141291576524081973
   PubMed Web of Science ®Google Scholar
• Boyer-NeumannCBrenotFWolfMContinuous infusion of prostacyclin decreases plasma levels of t-pa and pai-1 in primary pulmonary hypertensionThromb Haemost19957347357367495094
   PubMed Web of Science ®Google Scholar
• OgawaAMatsubaraHFujioHRisk of alveolar hemorrhage in patients with primary pulmonary hypertension – anticoagulation and epoprostenol therapyCirc J200569221622015671616
   PubMed Web of Science ®Google Scholar